Matthew Galsky, MD
img_Matthew Galsky
PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Cancer (Oncology)

MD, Tufts University

Residency, Internal Medicine, Beth Israel Deaconess Medical Center

Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center


American Society of Clinical Oncology Merit Award


Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)


Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)


Alpha Omega Alpha Honor Society


Selected Publications

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. Douglas B. Johnson, Michael B. Atkins, Cassandra Hennessy, Trisha Wise-Draper, Hannah Heilman, Joy Awosika, Ziad Bakouny, Chris Labaki, Renee Maria Saliby, Clara Hwang, Sunny R.K. Singh, Nino Balanchivadze, Christopher R. Friese, Leslie A. Fecher, James J. Yoon, Brandon Hayes-Lattin, Mehmet A. Bilen, Cecilia A. Castellano, Gary H. Lyman, Lisa Tachiki, Sumit A. Shah, Michael J. Glover, Daniel B. Flora, Elizabeth Wulff-Burchfield, Anup Kasi, Saqib H. Abbasi, Dimitrios Farmakiotis, Kendra Viera, Elizabeth J. Klein, Lisa B. Weissman, Chinmay Jani, Matthew Puc, Catherine C. Fahey, Daniel Y. Reuben, Sanjay Mishra, Alicia Beeghly-Fadiel, Benjamin French, Jeremy L. Warner, Sonya A. Reid, Alaina J. Brown, Alex Cheng, Sarah Croessmann, Elizabeth J. Davis, Kyle T. Enriquez, Erin A. Gillaspie, Daniel Hausrath, Gary K. Schwartz, Deborah B. Doroshow, Matthew D. Galsky, Michael Wotman. BMC Cancer

Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility. Alicia K. Morgans, Matthew D. Galsky, Phoebe Wright, Zsolt Hepp, Nancy Chang, Candice L. Willmon, Steve Sesterhenn, Yutong Liu, Guru P. Sonpavde. Urologic Oncology: Seminars and Original Investigations

Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. George Mellgard, Vaibhav G. Patel, Xiaobo Zhong, Himanshu Joshi, Qian Qin, Bo Wang, Anish Parikh, Tomi Jun, Parissa Alerasool, Philip Garcia, Mahalya Gogerly-Moragoda, Amanda Leiter, Emily J. Gallagher, William K. Oh, Matthew D. Galsky, Che Kai Tsao. Journal of Cancer Research and Clinical Oncology

View All Publications

Immune Checkpoint Blockade: A New Era in Cancer Treatment

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Galsky during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Bristol-Myers Squibb
  • Pfizer Inc.
  • NuMab
  • Incyte Corporation
  • Rappta Therapeutics
  • Curis Inc.
  • FUJIFILM Medical Systems U.S.A., Inc.
  • Genentech, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Alligator
  • Basilea
  • Silverback
  • AstraZeneca
  • Seattle Genetics

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Rappta Therapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.